ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2004
Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.
Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- Multimodal imaging for diagnosis and follow-up of primary vitreoretinal lymphoma: A systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study.Cancer science · 2011Trial
- Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2006Trial
- Ocular Imaging in Intraocular Lymphoma: A Review.Clinical & experimental ophthalmology · 2026Review
- Primary Central Nervous System Lymphoma as a Masquerade of Uveitis: A Case Report of Ocular Involvement.Cureus · 2026Article
- Exosome-Based Approaches in Regenerative Medicine and Targeted Therapy for Eye Malignancies: A Comprehensive Review.Eye and brain · 2026Review
- Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma.Japanese journal of ophthalmology · 2026Review
- [The DECODE VRL study-Multicenter implementation and clinical validation of standardized innovative molecular biological diagnostics for vitreoretinal lymphoma].Die Ophthalmologie · 2025Article
- Molecular analysis of bilateral T-cell vitreoretinal lymphoma.NPJ precision oncology · 2025Article
- Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).Eye and vision (London, England) · 2025Review
- Primary choroidal lymphoma with extrascleral extension and bone marrow involvement: a case report.Frontiers in medicine · 2025Article
- A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma.European journal of ophthalmology · 2024Review
- Optical coherence tomography features in vitreoretinal lymphoma compared with non-infectious uveitis.BMC ophthalmology · 2024Article
- Challenges in posterior uveitis-tips and tricks for the retina specialist.Journal of ophthalmic inflammation and infection · 2023Review
- Elevated interleukin-10 levels in patients with ocular toxoplasmosis.Parasites, hosts and diseases · 2023Article
- Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.Japanese journal of ophthalmology · 2023Review
- Choroidal biopsies; a review and optimised approach.Eye (London, England) · 2023Review
- Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single-center real-world clinical experience.Cancer medicine · 2023Article
- Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: a single tertiary center experience.Scientific reports · 2023Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary intraocular lymphoma (PIOL) is a rare non-Hodgkin lymphoma which arises in the retina or the vitreous. It can occur either together with or independently of primary cerebral nervous system lymphoma (PCNSL); the incidence of the latter has significantly increased over the past three decades. PIOL remains one of the most difficult diagnoses to establish, particularly due to its ability to mimic other diseases in the eye and to the limited material which is often available for examination.
methodsThe article reviews the clinical, histopathological, molecular biological and biochemical approaches to the diagnosis of PIOL. The differential diagnoses, including other lymphomatous manifestations in the eye, e.g. primary uveal lymphoma, as well as non-neoplastic uveal diseases are addressed. Furthermore, the treatment strategies for PIOL are summarised.
resultsDiagnostic progress has been made in various fields, including flow cytometry and immunocytology, cytokine analysis, and as well as molecular biological analysis of the immunoglobulin heavy and light chains using polymerase chain reaction on both fixed and non-fixed material. The optimal therapy of PIOL remains to be determined: the current trends suggest that combined radiotherapy and chemotherapy, as well as intravitreal chemotherapy, are of value. Novel therapies which may have a role in the future include oral trofosfamide.
conclusionOur understanding of the pathogenesis of PIOL/PCNSL remains far from complete. Intensified efforts must be made to determine the cell of origin of PIOL, as well as to establish "molecular signatures", which could be used to decrease diagnostic delay. Further studies, possibly prospective ones, are required to establish the optimal therapy for initial and recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.